SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-004274
Filing Date
2021-11-12
Accepted
2021-11-12 08:35:17
Documents
66
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20210930.htm   iXBRL 10-Q 3073907
2 EX-31.1 cadl-ex31_1.htm EX-31.1 17008
3 EX-31.2 cadl-ex31_2.htm EX-31.2 17691
4 EX-32.1 cadl-ex32_1.htm EX-32.1 9959
5 EX-32.2 cadl-ex32_2.htm EX-32.2 10416
  Complete submission text file 0000950170-21-004274.txt   8359984

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20210930.xsd EX-101.SCH 44957
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20210930_pre.xml EX-101.PRE 302186
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20210930_lab.xml EX-101.LAB 383417
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cadl-20210930_def.xml EX-101.DEF 201682
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cadl-20210930_cal.xml EX-101.CAL 32592
11 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20210930_htm.xml XML 1206969
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 211399969
SIC: 2836 Biological Products, (No Diagnostic Substances)